- Home
- URGN vs USPH Comparison
URGN vs USPH Comparison
Compare URGN & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URGN | USPH |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 1992 |
Fundamental Metrics
Financial Performance| Metric | URGN | USPH |
|---|---|---|
| Price | $22.72 | $78.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $28.50 | ★ $106.50 |
| AVG Volume (30 Days) | ★ 739.1K | 161.9K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.31% |
| EPS Growth | N/A | ★ 153.49 |
| EPS | N/A | ★ 2.38 |
| Revenue | $96,516,000.00 | ★ $750,948,000.00 |
| Revenue This Year | $27.96 | $19.53 |
| Revenue Next Year | $123.20 | $6.33 |
| P/E Ratio | ★ N/A | $32.86 |
| Revenue Growth | 8.00 | ★ 17.51 |
| 52 Week Low | $3.42 | $62.77 |
| 52 Week High | $30.00 | $93.50 |
Technical Indicators
Market Signals| Indicator | URGN | USPH |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 50.52 |
| Support Level | $22.50 | $79.10 |
| Resistance Level | $24.14 | $82.56 |
| Average True Range (ATR) | 1.18 | 2.63 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 40.94 | 26.68 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.